Multiple Sclerosis

The AJMC® Multiple Sclerosis compendium is a comprehensive resource for clinical news and expert insights for the disabling disease that impacts the brain and spinal cord.

Latest News

The MUSETTE trial did not meet its primary end point, suggesting a higher dose of IV ocrelizumab does not provide added benefits compared with the currently approved 600 mg dose. | Image credit: Chanintorn.v - stock.adobe.com
Higher-Dose Ocrelizumab Shows No Added Benefit vs Approved Dose in MS

April 9th 2025

The findings indicate that the currently approved 600-mg dose of intravenous ocrelizumab is optimal to significantly slow disability progression for patients with multiple sclerosis (MS).

MS wordcloud | Image Credit: © arloo-stock.adobe.com
5 Ongoing Clinical Trials Evaluating Treatment for MS

March 14th 2025

Kavita Nair Q&A - Maks_Lab - stock.adobe.com.jpeg
Coming Together to Ensure Neurological Treatment Access: Q&A With Kavita V. Nair, PhD

March 12th 2025

Ocrelizumab is approved as an IV infusion for relapsing and primary progressive forms of MS and as a subcutaneous injection, given twice a year. | Image credit: Trsakaoe - stock.adobe.com
Real-World Discontinuations of Ocrelizumab in MS Comparable to Pivotal Trials

January 9th 2025

Ocrelizumab is a monoclonal antibody that targets CD20 on B cells | image credit: molekuul.be - stock.adobe.com
Subcutaneous Ocrelizumab Well Tolerated in Patients With MS

January 8th 2025

Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain key insights into managing and understanding this condition.

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain valuable insights into managing and understanding this complex condition.
Continuing Medical Education
View All
April 15th 2025

Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment

1.5 Credits / Cardiology, Neurology, Rare Diseases
April 15th 2025

The Role of the Specialty Pharmacist in Optimizing Treatment for Amyotrophic Lateral Sclerosis: The Impact of Early Intervention, Patient-Centered Care, and Disease-Modifying Therapies in Slowing Disease Progression

1.0 Credit / Neurology
April 15th 2025

Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis

1.0 Credit / Immunology, Neurology
April 15th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
April 15th 2025

Overview and Burden of Migraine

0.5 Credit / Neurology
April 15th 2025

The Evolving Treatment Landscape of Migraine

0.5 Credit / Neurology
April 15th 2025

The Role of the Pharmacist Migraine Management

0.5 Credit / Neurology

More News

Antibodies in bloodstream
May 3rd 2021

B-Cell Depletion May Indicate Reduced COVID-19 Antibody Response Among Patients With MS

Maggie L. Shaw
New research demonstrates that patients with multiple sclerosis (MS) who were asymptomatic for COVID-19 had lower antibody levels against SARS-CoV-2, its causative virus, due to having fewer B cells.
Informational chart
April 30th 2021

DMT Uptake, Prescriptions Not Fitting Disease Course Among Patients With MS

Maggie L. Shaw
Because real-world data are lacking on disease-modifying treatment (DMT) prescribing patterns for patients with multiple sclerosis (MS), a team of investigators wanted to make sure these individuals were receiving adequate care.
Tracking patients
April 26th 2021

MS Care Not So Routine During the Pandemic

Maggie L. Shaw
Risk of infection topped the list of concerns among patients with multiple sclerosis (MS) who altered their usual care routines during the COVID-19 pandemic.
SARS-CoV-2 graphic
April 21st 2021

MS Patients on Ocrelizumab May Have Lessened Immune Response to SARS-CoV-2

Maggie L. Shaw
In an abstract presented at this year’s American Academy of Neurology annual meeting, patients with multiple sclerosis (MS) taking ocrelizumab had less of an immune reaction to infection with SARS-CoV-2, the virus that causes COVID-19.
Research
April 19th 2021

DMT Alone Not a Good Predictor of COVID-19 Among Patients With MS

Maggie L. Shaw
Compared with disease-modifying therapy (DMT), age, insurance status, and Hispanic ethnicity were shown to more accurately predict likelihood of COVID-19 and hospitalization from it among individuals with multiple sclerosis (MS).
health technology graphic
April 16th 2021

DMD Decision Aid Tool for Patients With MS Runs Into Efficacy Challenges

Gianna Melillo
An online tool developed to facilitate efficient patient-provider decisions on disease modifying drugs for multiple sclerosis (MS) ran into several challenges and warrants further study.
Female researcher
April 13th 2021

Clinical Surveillance Remains Necessary Among Cladribine-Treated Patients With RRMS

Maggie L. Shaw
A prospective bicentric cohort study among individuals with relapsing-remitting multiple sclerosis (RRMS) showed that 32% developed at least 1 skin-related adverse reaction following cladribine administration.
Image of fatigued person
April 10th 2021

Understanding the Patient Factors Linked to Fatigue in Multiple Sclerosis

Maggie L. Shaw
The advent of both new diagnostic criteria and treatments have necessitated a reevaluation of fatigue among individuals who have multiple sclerosis, investigators say.
Stack of books to be read
April 7th 2021

Review Explores Health Literacy in Patients With MS

Christina Mattina
Because health literacy can have different meanings for patients with different diseases, this review aimed to crystalize a definition in patients with multiple sclerosis (MS) and emphasize its importance in care planning.
Pill bottles
April 1st 2021

Infection Risk May Increase With Fingolimod Use in Patients With MS

Maggie L. Shaw
Among patients with multiple sclerosis, there is a 16% greater risk of infection, including for lower respiratory and herpes virus infections, after administration of fingolimod.
Neon neuron
March 30th 2021

Transcranial Direct Current Stimulation May Benefit Patients With MS

Maggie L. Shaw
With most current therapies for patients with multiple sclerosis (MS) targeting disease progression, a recent review evaluated transcranial direct current stimulation’s ability to improve certain disease symptoms.
Brain in gear
March 26th 2021

Researchers Identify 4 Distinct Phenotypes of Cognitive Impairment in MS

Maggie L. Shaw
Investigators aimed to close the knowledge gap on interindividual variability in cognitive evaluation outcomes by considering both cognitive impairment and mood disorders to better prediction accuracy.
Spoonfuls of supplements
March 24th 2021

Review Recommends Guidelines for Patients With MS Taking Herbal Drugs, Supplements

Maggie L. Shaw
With many patients with multiple sclerosis (MS) increasingly turning to herbal drugs and supplements to treat their disease, for which there is no cure, a recent review evaluated the safety of these alternative therapies.
Sick women
March 19th 2021

Risk Factors Identified That Predispose Patients With MS, COVID-19 to Worse Outcomes

Maggie L. Shaw
Among these factors, having a higher degree of disability from multiple sclerosis (MS) was independently associated with higher morbidity and mortality risks from having a comorbid case of COVID-19.
Various patient measurements
March 17th 2021

Infection Risk, Medical Claims High Among Patients With Multiple Sclerosis

Maggie L. Shaw
Patients with multiple sclerosis have high rates of urinary and kidney infections, inpatient hospitalizations, and outpatient hospital claims, according to recent results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis annual meeting.
Money for medicine
March 10th 2021

Medicare Part D Payments for MS Medications Outpace Inflation

Maggie L. Shaw
Investigators sought to better understand increasing price trends, including those seen among disease-modifying drugs to treat multiple sclerosis (MS) and other neurological diseases.
Warming group of people
March 5th 2021

Study Investigates Link Between Multiple Sclerosis, Warmer Weather

Maggie L. Shaw
Preliminary study results point to a possible connection between increasing global temperatures and an increased risk of hospitalization during the course of multiple sclerosis (MS).
Highlighted outline of a person's mind
March 2nd 2021

Mixed Improvements Seen Among Patients With MS Practicing Mindfulness

Maggie L. Shaw
A systematic review and meta-analysis of studies of patients with multiple sclerosis (MS) found that mindfulness- and acceptance-based interventions did not have a significant effect on mindfulness among these patients.
Group of happy kids
February 26th 2021

Researchers Highlight Need for Pediatric-Specific Treatment, Research for MS

Maggie L. Shaw
Compared with adult-onset multiple sclerosis (MS), pediatric-onset MS has few treatments directed at the condition, specifically those that promote remyelination, enhance neuroprotection, and remediate cognitive deficits.
research results
February 24th 2021

Amiselimod Most Effective S1P Receptor Modulator for Patients With MS

Maggie L. Shaw
Among 6 sphingosine-1-phosphate (S1P) receptor modulators evaluated for use in patients with multiple sclerosis (MS), a new meta-analysis shows amiselimod had the highest efficacy.
Progressive MS Alliance Seeks Change to Study Designs to Spur New Therapies
February 20th 2021

Progressive MS Alliance Seeks Change to Study Designs to Spur New Therapies

Skylar Jeremias
Advocates for patients with progressive multiple sclerosis (MS) want changes in study designs on emerging therapies to speed development and better align with the needs of researchers and patients.
Close-up of syringe and vial
February 19th 2021

MS Society Releases Guidance on DMT Dosing Modifications for COVID-19 Vaccination

Jaime Rosenberg
The current guidance emphasizes that the mRNA-based Pfizer/BioNTech and Moderna vaccines are safe for people with multiple sclerosis (MS) taking disease modifying therapies (DMTs).
Dr Burcu Zeydan Explains How Aging Impacts Multiple Sclerosis
February 12th 2021

Dr Burcu Zeydan Explains How Aging Impacts Multiple Sclerosis

Timing of relapses in multiple sclerosis is one of several interactions among aging, the trajectory of progressive disease, and worsening disability, according to Burcu Zeydan, MD, assistant professor of neurology, assistant professor of radiology, at the Mayo Clinic.
Higher Rates of Medication Adherence Seen in MS Compared With Other Chronic Diseases
February 11th 2021

Higher Rates of Medication Adherence Seen in MS Compared With Other Chronic Diseases

Gianna Melillo
Compared with patients with Parkinson disease, rheumatoid arthritis, or epilepsy, those with multiple sclerosis exhibited higher rates of medication adherence throughout the first year of treatment.
Sunlight Exposure Linked to Reduced Disease Severity in MS
February 6th 2021

Sunlight Exposure Linked to Reduced Disease Severity in MS

Skylar Jeremias
Investigators observed that some patients had improvements in their multiple sclerosis (MS) severity with increased sun exposure, whereas photosensitive individuals and those taking certain medications did not see the same effects.
Peer-Led Education Improves Health Literacy More Than Lectures for Patients With MS
February 6th 2021

Peer-Led Education Improves Health Literacy More Than Lectures for Patients With MS

Skylar Jeremias
Peer-led education was found to have a greater impact on multiple sclerosis (MS) health literacy than lecture-based education, a recent study from Iran demonstrated.
Researchers Describe 5 Cognitive Phenotypes in Multiple Sclerosis
January 30th 2021

Researchers Describe 5 Cognitive Phenotypes in Multiple Sclerosis

Allison Inserro
The findings suggest that this new categorization of cognitive deficits in multiple sclerosis may support clinicians in treatment choices and help tailor cognitive rehabilitation strategies, the authors said.
Degraded myelin sheath
January 26th 2021

Ongoing Review of DMTs Necessary Among Patients With Multiple Sclerosis

Larry Hanover
Periodic review of treatment safety and monitoring are necessary as medical centers increasingly use newer disease-modifying therapies earlier in the course of multiple sclerosis.
Top 5 multiple sclerosis stories of 2020
December 27th 2020

Top 5 Most-Read Multiple Sclerosis Articles of 2020

Christina Mattina
The coronavirus disease 2019 (COVID-19) pandemic dominated headlines for much of 2020, and most of the top 5 multiple sclerosis articles of this year discussed the effects of COVID-19 on patients with this disease. Others touched on physician and patient assessments of relapse and potential new treatments for neural damage.
Researchers Review Available Efficacy, Safety Data on Ozanimod in RMS
December 23rd 2020

Researchers Review Available Efficacy, Safety Data on Ozanimod in RMS

Jaime Rosenberg
Researchers analyzed the available evidence on the treatment’s efficacy and safety profile from the RADIANCE and SUNBEAM trials.
<12345678910
...
21>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo